Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
159 hedge funds and large institutions have $2.26B invested in Intercept Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 66 increasing their positions, 44 reducing their positions, and 34 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 44
1% less call options, than puts
Call options by funds: $145M | Put options by funds: $147M
8% less funds holding
Funds holding: 172 → 159 (-13)
33% less capital invested
Capital invested by funds: $3.37B → $2.26B (-$1.11B)
35% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.2M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$11.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$47.4M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$31.7M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$25M |
| 4 |
CCI
Columbus Circle Investors
|
-$14.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$14.1M |
ICPT Hedge Fund Activity: Q4 2016 in Review
159 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2016, worth a combined $2.26B — down 33% from $3.37B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ICPT and 22 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 66 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $23.2M. The largest seller was Citadel Advisors, cutting an estimated $47.4M.
- 159 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2016, down from 172 in Q3 2016.
- Funds reported $2.26B of Intercept Pharmaceuticals, Inc. stock for Q4 2016, down 33% quarter-over-quarter.
- 22 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2016 and 34 closed out, a net change of -12 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2016 was Point72 Asset Management, an estimated $23.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2016 was Citadel Advisors, an estimated $47.4M sold.
Based on aggregated 13F filings for Q4 2016.